FCMI
Foresite Capital Management III Portfolio holdings
AUM
$37.9M
This Quarter Return
+21.59%
1 Year Return
-6.87%
3 Year Return
+443.49%
5 Year Return
+535.97%
10 Year Return
–
AUM
$86M
AUM Growth
+$86M
(-36%)
Cap. Flow
-$58.5M
Cap. Flow
% of AUM
-67.98%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
2
Reduced
1
Closed
2
Top Buys
| 1 |
Aclaris Therapeutics
ACRS
|
$6.05M |
| 2 |
FibroGen
FGEN
|
$4.94M |
Top Sells
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$54.4M |
| 2 |
Natera
NTRA
|
$8.11M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$6.93M |
Sector Composition
| 1 | Healthcare | 80.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
1
DELISTED
Acceleron Pharma Inc.
XLRN
| $13.9M | 16.15% | 108,630 | – | – |
|
|
2
Natera
NTRA
$23.1B
| $12.7M | 14.73% | 127,305 -81,463 | -39% | -$8.11M |
|
|
3
FibroGen
FGEN
$47.8M
| $11.3M | 13.18% | 305,784 +133,284 | +77% | +$4.94M |
|
|
EPZM
4
DELISTED
Epizyme, Inc
EPZM
| $10.8M | 12.6% | 998,278 | – | – |
|
|
5
Aclaris Therapeutics
ACRS
$209M
| $10.5M | 12.18% | 1,620,244 +935,332 | +137% | +$6.05M |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $9.42M | 10.95% | 1,641,804 | – | – |
|
7
Novavax
NVAX
$1.21B
| $558K | 0.65% | 5,000 | – | – |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| – | – | -1,111,112 | Closed | -$6.93M |
|
|
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| – | – | -399,360 | Closed | -$54.4M |
|